Trials / Completed
CompletedNCT01494233
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 373 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 250 mg LX1033 tablets | 250 mg LX1033 tablets administered orally |
| DRUG | Placebo tablet | Matching placebo tablet administered orally |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-09-01
- First posted
- 2011-12-16
- Last updated
- 2015-03-23
Locations
81 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01494233. Inclusion in this directory is not an endorsement.